Arrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings Results

Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38), FiscalAI reports. The business had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a negative return on equity of 0.37% and a negative net margin of 0.20%.The business’s revenue was up 10461.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.39) EPS.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

• Redemplo received U.S. FDA approval (Nov 18, 2025) for FCS, launched commercially with an 80% median TG reduction in PALISADE, a favorable label (no warnings/contraindications) and >100 prescriptions plus encouraging payer feedback and shipments to date.
• Arrowhead materially strengthened its balance sheet with ~$1.33 billion of transactions (Novartis $200M upfront, Sarepta $200M milestone, $700M convertible notes and $230M equity), leaving cash/investments around $917M plus additional near-term receipts to fund multiple launches and development programs.
• Plozasiran’s global Phase III program (SHASTA‑3/4, NEAR‑3) remains on track (blinded completion mid‑2026) with top‑line readout expected Q3 2026 and a planned sNDA for SHTG by year‑end, positioning a potential large ($3–4B) market expansion beyond FCS.
• Early pipeline advances are promising but preliminary: ARO‑INHBE showed ~2x weight loss vs tirzepatide + significant fat reductions in obese T2D patients, ARO‑ALK7 demonstrated dose‑dependent adipose mRNA knockdown, ARO‑DimerPA is dosed in Phase 1/2 (interim H2 2026), and ARO‑MAPT (BBB delivery) has first human dosing with healthy volunteer data expected in 2026; additional data are needed to de‑risk commercial potential.

Arrowhead Pharmaceuticals Trading Down 5.0%

NASDAQ ARWR opened at $64.64 on Friday. The firm’s fifty day moving average is $66.63 and its two-hundred day moving average is $43.09. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $76.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market cap of $9.05 billion, a PE ratio of -807.90 and a beta of 1.21.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 13,187 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the completion of the sale, the chief executive officer directly owned 3,792,739 shares of the company’s stock, valued at $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mauro Ferrari sold 7,530 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the transaction, the director owned 69,053 shares in the company, valued at approximately $4,833,710. This trade represents a 9.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 510,836 shares of company stock worth $33,603,060 over the last quarter. 3.60% of the stock is owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently made changes to their positions in ARWR. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. Quadrant Capital Group LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth about $140,000. Daiwa Securities Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 3,763 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $91,000. Finally, Velan Capital Investment Management LP purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $224,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the subject of several recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Bank of America lifted their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, January 21st. The Goldman Sachs Group raised their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, January 7th. Finally, B. Riley boosted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.